Compare GSK plc (GSK) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ProShares Ultra Gold ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while ProShares Ultra Gold ETF trades at $46.45 (market cap $716.59M). The key difference: GSK plc is far larger — about 128.2× ProShares Ultra Gold ETF's market cap, and GSK plc pays a 3.9% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and ProShares Ultra Gold ETF for 23 Days on average.
| GSK | UGL | |
|---|---|---|
Market Cap | $91.88B | $716.59M |
Volume | 7,730,529 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $85.62 |
52-Week Low | $43.24 | $42.79 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
UGL is trading at $45.08, up 1.46% today, but faces significant technical headwinds with a bearish overall signal. The stock shows neutral momentum oscillators but bearish moving averages, with key support at $44 and resistance at $46. Recent market sentiment reflects uncertainty around Federal Reserve policy and Treasury yield pressures affecting gold-related assets.
The outlook remains cautious as UGL navigates macroeconomic pressures including interest rate uncertainty and dollar strength. While technical indicators suggest near-term weakness, the stock's proximity to support levels may offer tactical opportunities for patient investors. Key risks include continued Fed hawkishness and gold price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
